Merck and its partner Daiichi Sankyo announced today that the first patient has received a dose in a phase 2/3 trial evaluating the efficacy and safety of the investigational raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer.

The phase 2 portion of the trial will be conducted to identify the dose of raludotatug deruxtecan to be used in the phase 3 portion of the trial, which will evaluate raludotatug deruxtecan versus chemotherapy treatment.

Raludotatug deruxtecan is a specially designed antibody-drug conjugate (ADC) discovered by Daiichi Sankyo and jointly developed with Merck.

We look forward to working with our colleagues at Daiichi Sankyo to further evaluate the potential of raludotatug deruxtecan to provide a new treatment option for patients with platinum-resistant ovarian cancer," commented Marjorie Green, Senior Vice President and Head of Late Stage Oncology, Global Clinical Development, Merck Research Laboratories.

Copyright (c) 2024 All rights reserved.